CAMBRIDGE, Massachusetts—Researchers from the University of Copenhagen, Insilico Medicine, and international academic partners have identified a previously unrecognized vulnerability in cancer DNA damage repair, centered on the stress-response protein NDRG1. Published in Science Signaling on July 21, 2026, the study reports that disrupting the NDRG1–VCP interaction can selectively damage cancer cells with particular DNA repair defects, including colorectal cancer cells carrying mutations in MLH1 or PARP3. The work also identifies the antimalarial drug quinacrine as a tool compound capable of triggering this effect, offering a potential starting point for the development of more selective precision-oncology therapies.
DNA damage repair is one of the most important survival systems in a cancer cell. Tumors often accumulate mutations that disable one repair pathway while leaving other mechanisms intact. As a result, malignant cells can become unusually dependent on the repair processes that remain functional. This phenomenon, known as synthetic lethality, creates an opportunity to kill tumor cells while limiting damage to normal tissues. The best-known example is the sensitivity of BRCA1- or BRCA2-deficient tumors to PARP inhibitors. The new study suggests that NDRG1 may provide another entry point into this strategy by controlling how cancer cells respond to DNA damage.
NDRG1, or N-myc downstream-regulated gene 1, is a stress-responsive protein involved in cellular adaptation, differentiation, metabolism, and cancer biology. Although its expression has previously been associated with tumor progression and patient outcomes in several cancer types, its direct role in DNA repair had not been fully defined. The researchers found that NDRG1 participates in the organization of a molecular response to DNA lesions through its interaction with VCP, also known as valosin-containing protein. VCP is an ATP-dependent molecular machine that helps extract, remodel, and process ubiquitylated proteins in a wide range of cellular pathways.
The investigation began with computational analysis rather than a conventional search through large chemical libraries. The team compared gene-expression signatures associated with DNA damage with extensive datasets describing how cells respond to genetic and pharmacological perturbations. This approach highlighted quinacrine, a decades-old antimalarial and antiparasitic drug, as a candidate modulator of DNA damage response pathways. The computational prediction did not by itself establish how the compound worked, but it provided a testable biological hypothesis that could be examined using cell-based experiments and molecular assays.
Subsequent laboratory studies connected quinacrine’s activity to NDRG1. The researchers reported that the compound interferes with the interaction between NDRG1 and VCP, disrupting a process required for the correct recruitment and maintenance of DNA repair factors. In normal repair signaling, proteins modified by ubiquitin can be directed to sites of DNA damage, where they coordinate the recognition and repair of broken or damaged DNA. By weakening the NDRG1–VCP complex, quinacrine promoted the degradation or mislocalization of proteins involved in this response. The result was impaired repair signaling and increased vulnerability to DNA damage.
The team combined mechanistic molecular biology with high-content genetic screening and large-scale cancer-cell profiling. More than 130 cancer cell lines representing 28 cancer types were examined to determine which tumors were most sensitive to quinacrine or to experimental reduction of NDRG1. The strongest patterns emerged in cells with elevated NDRG1 expression and specific defects in DNA repair. Colorectal cancer models carrying mutations in MLH1 or PARP3 were particularly sensitive, indicating that the NDRG1 pathway may become essential when these repair-associated genes are lost.
MLH1 is a central component of the DNA mismatch repair system, which corrects errors introduced during DNA replication. Loss of MLH1 can produce widespread genomic instability and is a defining feature of many mismatch-repair-deficient colorectal tumors. PARP3, meanwhile, belongs to the poly(ADP-ribose) polymerase family and contributes to the cellular response to DNA breaks and chromatin-associated damage. The study suggests that when either pathway is compromised, tumor cells may rely more heavily on NDRG1-dependent repair processes. Blocking that remaining support could push the cells beyond their capacity to survive accumulated DNA lesions.
Patient-data analyses added a further layer to the findings. Across multiple cancer types, the researchers examined relationships between NDRG1 expression, DNA repair gene status, and clinical outcomes. Their analyses indicated that loss of MLH1 or PARP3 was associated with improved survival among patients whose tumors expressed high levels of NDRG1. These observations do not establish that NDRG1 directly determines patient prognosis, nor do they prove that quinacrine would be effective as a cancer treatment. They do, however, support the idea that NDRG1 expression and DNA repair genotype could eventually help identify tumor populations for experimental therapies targeting this pathway.
The researchers emphasize that quinacrine was used as an experimental tool compound rather than presented as a ready-made oncology treatment. Its established medical history may simplify some aspects of drug development, but its pharmacology, selectivity, dosing, and safety profile would need to be reassessed carefully in cancer patients. Quinacrine affects multiple biological processes, and the concentration required to disrupt NDRG1-related repair mechanisms in laboratory models may not correspond to a safe or effective exposure in humans. The immediate significance of the work is therefore the biological discovery: NDRG1 appears to act as a regulator of DNA damage repair and may represent a druggable dependency in genetically defined cancers.
The study also illustrates how artificial intelligence and computational biology are changing the early stages of biomedical research. Rather than replacing laboratory experiments, the computational analysis narrowed a vast field of possible chemical and genetic relationships into a focused hypothesis that could be tested experimentally. Genetic screening, cancer-cell profiling, patient-survival analysis, and molecular studies then reinforced one another, transforming an initial computational signal into a mechanistic model. The authors now hope that the NDRG1–VCP pathway can guide the design of more selective compounds and combination strategies for tumors with defined DNA repair deficiencies. If validated in further preclinical and clinical studies, the discovery could expand the growing field of synthetic-lethal cancer therapies and provide a new route for attacking tumors that have become dependent on their last remaining repair systems.
Subject of Research: NDRG1-mediated DNA damage repair and synthetic lethality in genetically defined cancers.
Article Title: “NDRG1 expression in cancers confers dependence on DNA damage repair and sensitivity to quinacrine”
News Publication Date: August 10, 2026
Web References: Insilico Medicine, https://www.insilico.com; DOI: https://doi.org/10.1126/scisignal.adv4272
References: Mkrtchyan GV, Veviorskiy A, Meisen ZG, Petr MA, Mercurio TC, Bakula D, et al. “NDRG1 expression in cancers confers dependence on DNA damage repair and sensitivity to quinacrine.” Science Signaling. Published July 21, 2026. DOI: 10.1126/scisignal.adv4272.
Keywords: NDRG1, DNA damage repair, synthetic lethality, quinacrine, VCP, colorectal cancer, MLH1, PARP3, precision oncology, artificial intelligence, cancer biology
